Hematopoietic cell transplantation (HCT) provides a life-prolonging or potentially curative treatment option for patients with hematologic malignancies.

The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates.

No effective systemic treatment exists for malignant peripheral nerve sheath tumors (MPNSTs).

The 2013 NCCN Clinical Practice Guidelines in Oncology address the evaluation and management of patients at risk of inherited susceptibility to colorectal cancer.

Randomized trials support the use of neoadjuvant chemotherapy in muscle-invasive bladder cancer due to a noted survival advantage, which appeared to be strongly related to downstaging of the cancer to pT0 (complete pathologic response).

The 2014 NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous Leukemia recommend quantitative reverse-transcription polymerase chain reaction (qRT-PCR) standardized to International Scale (IS) as the preferred method for monitoring molecular response to tyrosine kinase inhibitor

Cancer-associated retinopathy (CAR) is a rare autoimmune condition associated with various cancers, causing significant visual impairment.

Venous thromboembolism (VTE) has serious consequences for patients with cancer, including mortality. VTE is preventable with appropriate thromboprophylaxis, but prior public health efforts have focused on prophylaxis in the inpatient setting.

Colorectal cancer is a common and significant public health concern. The liver is the most common site of metastasis, and colorectal cancer liver metastases (CRLM) may affect up to 60% of patients at some time during the course of their disease.

These NCCN Guidelines Insights focus on the major updates to the 2013 NCCN Guidelines for Ovarian Cancer. Four updates were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials.